Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
The Tumor Microenvironment02:17

The Tumor Microenvironment

7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.0K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

6.5K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Engineering of Artificial Antioxidase Enables Boosted Catalytic Activity in Inflammatory Bowel Disease Alleviation.

Angewandte Chemie (International ed. in English)·2026
Same author

Bioinspired Molecular Engineering of IRE1-Gated DNAzymes for Self-Adaptive Bidirectional Modulation of ER Stress.

Angewandte Chemie (International ed. in English)·2026
Same author

Retraction Note: NIR-light-mediated spatially selective triggering of anti-tumor immunity via upconversion nanoparticle-based immunodevices.

Nature communications·2026
Same author

Topology-Informed Design of Circularly Locked DNAzymes Enables Orthogonally Controlled Gene Regulation.

Journal of the American Chemical Society·2026
Same author

Senescence-Primed Ferroptosis Enabled by a Metal-Organic Framework Nanoplatform for Enhanced Cancer Therapy.

ACS nano·2025
Same author

Ultrasensitive Profiling of Extracellular Vesicles by a Microbead- and Aptamer-Enhanced Thermophoretic Assay for Monitoring Therapeutic Responses.

Analytical chemistry·2025

Related Experiment Video

Updated: Jan 16, 2026

Synthesis of Immunotargeted Magneto-plasmonic Nanoclusters
09:43

Synthesis of Immunotargeted Magneto-plasmonic Nanoclusters

Published on: August 22, 2014

15.7K

Multivalent Metal-Nucleotide Nanoagonists Amplify Innate Immune Activation for Cancer Metalloimmunotherapy.

Yanjuan Huang1,2, Yike Li1,2, Ziwei Han1,2

  • 1Beijing Engineering Research Center for BioNanotechnology, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, National Center for Nanoscience and Technology, Beijing 100190, China.

Nano Letters
|October 3, 2025
PubMed
Summary
This summary is machine-generated.

Researchers developed novel metal-nucleotide nanoagonists (Mn-MNAs) to boost cancer immunotherapy. These nanoagonists enhance immune responses by activating key pathways, showing significant tumor inhibition and improved therapeutic efficacy.

Keywords:
cancer metalloimmunotherapycoordinationinnate immune activationmetal−nucleotidenanoagonists

More Related Videos

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
09:28

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

12.0K
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.4K

Related Experiment Videos

Last Updated: Jan 16, 2026

Synthesis of Immunotargeted Magneto-plasmonic Nanoclusters
09:43

Synthesis of Immunotargeted Magneto-plasmonic Nanoclusters

Published on: August 22, 2014

15.7K
Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles
09:28

Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles

Published on: November 17, 2018

12.0K
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.4K

Area of Science:

  • Biomedical Engineering
  • Immunology
  • Nanotechnology

Background:

  • Metalloimmunotherapy utilizes metal ions for cancer treatment, but low bioavailability of metal ions and agonists limits effectiveness.
  • Robust stimulation of antitumor immune responses is crucial for effective cancer immunotherapy.

Purpose of the Study:

  • To develop multivalent metal-nucleotide nanoagonists (Mn-MNAs) to enhance the stability and cellular uptake of immune agonists.
  • To amplify antitumor immunity by concurrently activating the stimulator of interferon genes (STING) and toll-like receptor 9 (TLR9) pathways.

Main Methods:

  • Synthesized Mn-MNAs via aqueous coordination of nucleotide-based innate immune agonists with Fe2+ and Mn2+.
  • Evaluated Mn-MNAs for enhanced stability and cellular uptake of agonists.
  • Assessed the activation of STING and TLR9 pathways by Mn-MNAs.
  • Tested intratumoral and intravenous administration of Mn-MNAs in CT26 and B16F10 tumor models, respectively.

Main Results:

  • Mn-MNAs demonstrated enhanced stability and cellular uptake of immune agonists.
  • Concurrent activation of STING and TLR9 pathways was achieved by Mn-MNAs.
  • Intratumoral injection of Mn-MNAs significantly inhibited tumor growth in the CT26 model.
  • Intravenous administration of Mn-MNAs showed remarkable efficacy in the B16F10 melanoma model, further improved with checkpoint blockade.

Conclusions:

  • Multivalent metal-nucleotide nanoagonists represent a promising strategy for enhancing cancer immunotherapy.
  • Mn-MNAs offer a novel approach to overcome bioavailability limitations and amplify antitumor immunity.
  • This work opens new avenues for cancer metalloimmunotherapy development.